Anika Therapeutics
ANIK
103 hedge funds and large institutions have $134M invested in Anika Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 21 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
0.96% less ownership
Funds ownership: 89.41% → 88.45% (-0.96%)
5% less funds holding
Funds holding: 108 → 103 (-5)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
30% less capital invested
Capital invested by funds: $191M → $134M (-$56.5M)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.45M |
| 2 |
CM
Capital Management
Glen Allen,
Virginia
|
+$999K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$972K |
| 4 |
Millennium Management
New York
|
+$708K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Meros Investment Management
Dallas,
Texas
|
-$2.61M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$591K |
| 3 |
D.E. Shaw & Co
New York
|
-$551K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$507K |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$413K |
ANIK Hedge Fund Activity: Q2 2025 in Review
103 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2025, worth a combined $134M — down 30% from $191M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANIK and 16 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was Opaleye Management, adding an estimated $2.45M. The largest seller was Meros Investment Management, exiting entirely with an estimated $2.61M sold.
- 103 institutional investors held Anika Therapeutics (ANIK) as of Q2 2025, down from 108 in Q1 2025.
- Funds reported $134M of Anika Therapeutics stock for Q2 2025, down 30% quarter-over-quarter.
- 16 funds opened new Anika Therapeutics positions in Q2 2025 and 21 closed out, a net change of -5 holders.
- The largest Anika Therapeutics buyer in Q2 2025 was Opaleye Management, an estimated $2.45M added.
- The largest Anika Therapeutics seller in Q2 2025 was Meros Investment Management, an estimated $2.61M sold.
Based on aggregated 13F filings for Q2 2025.